Teon Therapeutics, Inc.

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Teon Therapeutics is a private biopharma start-up developing a portfolio of single-target small molecules that affect metabolic signaling pathways in the tumor microenvironment. Our pipeline includes synergistic biological targets, combining first-in-class and best-in-class candidates. Teon's lead program is an A2BR antagonist that is built upon the shortcomings of 1st-generation adenosine candidates and will enter Phase 1b trials in 2021. Our experienced leadership team is executing a tried-and-true strategy espoused by Gilead - develop high-specificity, single-target therapeutics.
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
TT-702 (A2BR antagonist)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
President & COO
Teon Therapeutics, Inc.